Abstract
A wide range of established treatment options is currently available for myasthenia gravis. These include cholinesterase inhibitors for symptomatic treatment and a broad spectrum of immunosuppressive, immunomodulating or cell-depleting options to modify the underlying immunological process. Appropriate use allows the great majority of patients to lead a normal life. Specialized centers integrating outpatient and in-hospital resources as well as interdisciplinary competences offer important advantages for optimum individualized therapy.
Cite
CITATION STYLE
Paul Urban, P., Jacobi, C., & Jander, S. (2018). Treatment Standards and Individualized Therapy of Myasthenia Gravis. Neurology International Open, 2(02), E84–E92. https://doi.org/10.1055/s-0043-124983
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.